Molecular Targets for the Novel Therapies of Inflammation and Wound Care

Abstract

Anti-inflammatory drugs, particularly steroidal and non-steroidal, are already the sole treatment options for inflammatory illnesses. Chronic use of these medicines has been linked to gastrointestinal, cardiovascular, as well as other serious side effects. New anti-inflammatory and wound healing drugs with selective effect and lower toxicity are desperately needed. Novel therapies acting on different molecular targets have shown promising resultsRelevant studies (2003-2024) were identified through electronic searches of PubMed and Google scholar. The search used the keywords, including the following inflammation, wound care, signalling pathways, molecular targets of inflammation. Neutrophils and macrophages play a significant role in the release of mediators and phagocytosis at the site, Nf-kB signaling pathway and the JAK/Stat signaling pathway stimulate the production of mediators including IL-6, IL-1, and TNF-α, although their overproduction can have a variety of consequences. Cell therapy, MicroRNA, plasma protein therapy, COX-2 inhibitor with stem cells, combination of AMD3100 and Tacrolimus and combination of siRNAs with Plurogel for increasing wound healing time are among the approved and continuing clinical trial novel therapies mentioned. This study shows that these new therapeutics can interact with numerous targets and modify the dysregulated inflammatory pathways and mediators associated with normal and chronic wounds more effectively than standard anti-inflammatory medication treatments.